Skip to main
XRAY
XRAY logo

DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target

DENTSPLY SIRONA (XRAY) Analyst Ratings

Based on 24 analyst ratings
Hold
Strong Buy 17%
Buy 25%
Hold 54%
Sell 4%
Strong Sell 0%

Bulls say

Dentsply Sirona has demonstrated positive sales performance, with a reported sales growth of 2.8% in Europe and a 1.8% organic growth, indicating resilience in its core markets. Additionally, the company is poised for accelerating revenue growth in the mid-single digits over the coming years, supported by potential drivers such as a recovery in the implants segment and market share gains in clear aligners. Furthermore, Wellspect Healthcare's strong revenue generation, which exceeded expectations and grew 6.7% organically, highlights Dentsply Sirona's capability to enhance margins and overall earnings performance.

Bears say

Dentsply Sirona's recent financial performance has been characterized by significant underperformance, exemplified by an adjusted EPS of $0.26 that fell short of expectations by a substantial margin. Additionally, the connected technology solutions (CTS) segment experienced an 8.3% decline in revenue, compounded by increased operating expenses and a gross margin decrease of 240 basis points year-over-year, which further strained profitability. The impact of the Byte shutdown resulted in a notable loss of $62 million in revenue and a $0.24 reduction in adjusted EPS, contributing to a negative outlook for the company's financial health amid restructuring and integration challenges.

DENTSPLY SIRONA (XRAY) has been analyzed by 24 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 25% recommend Buy, 54% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DENTSPLY SIRONA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DENTSPLY SIRONA (XRAY) Forecast

Analysts have given DENTSPLY SIRONA (XRAY) a Hold based on their latest research and market trends.

According to 24 analysts, DENTSPLY SIRONA (XRAY) has a Hold consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DENTSPLY SIRONA (XRAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.